Home Cart Sign in  
Chemical Structure| 473719-41-4 Chemical Structure| 473719-41-4

Structure of AMG 487
CAS No.: 473719-41-4

Chemical Structure| 473719-41-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AMG-487 is a small molecule antagonist of the chemokine receptor CXCR3 and inhibits binding of 125I-IP-10 and 125I-ITAC to CXCR3.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AMG 487

CAS No. :473719-41-4
Formula : C32H28F3N5O4
M.W : 603.59
SMILES Code : O=C(N([C@@H](C1=NC2=NC=CC=C2C(N1C3=CC=C(OCC)C=C3)=O)C)CC4=CC=CN=C4)CC5=CC=C(OC(F)(F)F)C=C5
MDL No. :MFCD11111772
InChI Key :WQTKNBPCJKRYPA-OAQYLSRUSA-N
Pubchem ID :24957182

Safety of AMG 487

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of AMG 487

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse microglia BV2 cells 2.5 μM 24 h AMG487 significantly inhibited PF4-mediated JEV replication in mouse microglia cells. EBioMedicine. 2019 Jan;39:332-347
human monocytes 2.5 μM 24 h AMG487 significantly inhibited PF4-mediated DV2 replication in monocytes and rescued IFN-α secretion. EBioMedicine. 2019 Jan;39:332-347
Panc-1 and Panc02 cells 5 nM 48 h Evaluate the effect of AMG 487 on cell cycle and EMT-related proteins in Panc-1 and Panc02 cells, results showed that AMG 487 partially reversed the effects of MFAP5_OE CAFs Oncogene. 2023 Jun;42(25):2061-2073
GSC16 cells 25, 50 μM 17 days To evaluate the effect of AMG487 on the spheroid size of GSC16 cells, results showed that AMG487 reduced spheroid size in a dose-dependent manner. Cell Death Discov. 2025 Apr 4;11(1):143
U251 cells 0.8, 1.6, 3.2 μM 72 h To evaluate the effect of AMG487 on the viability of U251 cells, results showed that AMG487 reduced cell viability in a dose-dependent manner. Cell Death Discov. 2025 Apr 4;11(1):143
U87 cells 0.8, 1.6, 3.2 μM 72 h To evaluate the effect of AMG487 on the viability of U87 cells, results showed that AMG487 reduced cell viability in a dose-dependent manner. Cell Death Discov. 2025 Apr 4;11(1):143
SAOS-LM7 cells 1 μM 18 h decreased migration, decreased matrix metalloproteinase activity, decreased proliferation/survival and increased caspase-independent death Int J Cancer. 2009 Dec 1;125(11):2586-94

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish Tg(fli1a:eGFP)y1; Tg(kdrl:mCherry-CAAX)y171; TgBAC(pdgfrb:Gal4FF)ncv24; Tg(5xUAS:RFP)zf83; Tg(kdrl:rpl10a-3xHA-2a-eGFP)y530; TgBAC(cdh5:cdh5-TS)uq11bhTg; Tg(fli1:H2B-mCherry)uq37bhTg Added to zebrafish water 50 µmol/L 32 hpf to 54 hpf To study the role of CXCR3 in zebrafish cranial vascular development, results showed that suppression of Cxcr3 activity (AMG487) promoted expansion of the vascular network, while activation of Cxcr3 activity (VUF11222) inhibited expansion of the vascular network. Arterioscler Thromb Vasc Biol. 2024 Dec;44(12):2577-2595
C57BL/6 mice Pancreatic cancer xenograft model Intraperitoneal injection 5 mg/kg 3 times a week for 2 weeks Evaluate the effect of AMG 487 on pancreatic cancer xenograft models, results showed that AMG 487 partially reversed the pro-tumor effect of MFAP5 overexpression in CAFs and synergized with anti-PD-L1 antibody to enhance immunotherapeutic effect Oncogene. 2023 Jun;42(25):2061-2073
Mice Congenital Hepatic Fibrosis model Oral 5 mg/kg 4 times/week for 3 months Evaluate the effect of AMG-487 on disease progression. Results showed AMG-487 significantly reduced CD45+ immune cell infiltration (47% reduction), K19-positive cyst area (37% reduction), collagen deposition (53% reduction), and splenomegaly (35% reduction). Hepatology. 2018 May;67(5):1903-1919
Mice LPS-induced periodontitis model Intraperitoneal injection 5 mg/g Twice daily for 6 weeks To evaluate the effect of AMG-487 on LPS-induced periodontal bone loss. Results showed that AMG-487 significantly reduced bone loss and osteoclast numbers. J Bone Miner Res. 2018 Aug;33(8):1450-1463
C57BL/6J male mice LPS-induced periodontitis model Local injection 0.5 μM Twice a week for 6 weeks To evaluate the effect of locally delivered CXCR3 antagonist on inflammation, osteoclastic activity, and bone loss. Results showed that AMG-487 NP significantly reduced bone loss and osteoclast numbers. Clin Oral Investig. 2022 Aug;26(8):5163-5169
Mice Non-alcoholic steatohepatitis (NASH) model 5 mg/kg Daily administration for 10 days Evaluate the effect of CXCR3 antagonist AMG487 on mitochondrial function. Results showed that AMG487 significantly improved mitochondrial function, evidenced by increased mitochondrial fusion protein MFN1 and decreased fission proteins DRP1 and FIS1, along with reduced mitochondrial-related apoptosis. Theranostics. 2017 Sep 26;7(17):4192-4203
Medaka (Oryzias latipes) Osteoporosis model Yolk injection and immersion in fish medium 20 μM Injected 3 hours before heat shock and then continuously cultured in drug-containing medium AMG487 reduces macrophage recruitment to bone matrix and osteoclast differentiation by inhibiting Cxcr3.2, thereby protecting bone integrity from osteoporotic insult. Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19276-19286
Nude mice U87 cell xenograft model Subcutaneous injection 10 mg/kg 10 consecutive days To evaluate the effect of AMG487 on tumor growth in the U87 cell xenograft model, results showed that AMG487 significantly reduced tumor intensity and size. Cell Death Discov. 2025 Apr 4;11(1):143
BALB/c and nude mice Osteosarcoma lung metastasis models Subcutaneous injection 5 mg/kg Twice daily, from Day –1 to Day +3 (K7M2 model) and from Day –1 to Day +5 (SAOS-LM7 model) Prevent and treat osteosarcoma lung metastasis, significantly reducing metastatic disease Int J Cancer. 2009 Dec 1;125(11):2586-94

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.66mL

0.33mL

0.17mL

8.28mL

1.66mL

0.83mL

16.57mL

3.31mL

1.66mL

References

 

Historical Records

Categories